ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

Figure 4 Relapse-free survival curves of gastric cancer patients according to ERCC1 mRNA expression and ERCC1 118 C/T polymorphism relapse-free survival curves according to ERCC1 mRNA expression (A) or ERCC1 118 polymorphism (B). The relapse-free survival in patients with high levels of ERCC1 mRNA (> 0.672) was significantly poorer than that in patients with low levels (≤ 0.672) (P < 0.05), while there was no significant difference between patients with ERCC1 118 C/C and variant genotypes (T/T or C/T).